Physician profile
Marcela Vargas Trujillo
NPI 1952534091
$56,812.84
in general payments reported to CMS, 2019-2025
23 companies · $14K in 2025
The $14K reported for 2025 was more than what 91% of Pediatric Endocrinology providers received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,295 · 2020: $326 · 2021: $126 · 2022: $9,531 · 2023: $17K · 2024: $15K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Consulting Fee: $13K · Honoraria: $11K · Food and Beverage: $2,200 · Travel and Lodging: $648.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,500.00 |
| Consulting Fee | $13,262.50 |
| Honoraria | $10,925.00 |
| Food and Beverage | $2,199.56 |
| Travel and Lodging | $648.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $30,916.25 | 2019-2025 | Lupron Depot |
| Tolmar, INC. | $13,357.53 | 2023-2025 | Fensolvi |
| Tolmar Pharmaceuticals, INC. | $9,506.79 | 2022 | |
| Novo Nordisk INC | $475.73 | 2019-2025 | Sogroya, Wegovy |
| Ferring Pharmaceuticals INC. | $350.11 | 2019-2020 | |
| Dexcom, INC. | $327.11 | 2020-2025 | Dexcom G6 Transmitter |
| Ipsen Biopharmaceuticals, INC | $279.25 | 2019-2020 | |
| Tandem Diabetes Care, INC. | $208.57 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Beta Bionics, INC. | $195.85 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Insulet Corporation | $188.26 | 2019-2025 | Omnipod |
| Pfizer INC. | $111.78 | 2019-2025 | |
| Ascendis Pharma Endocrinology INC | $111.63 | 2022-2025 | Skytrofa |
| Arbor Pharmaceuticals, INC. | $101.64 | 2019-2020 | |
| Eton Pharmaceuticals, INC. | $101.15 | 2025 | Khindivi, Increlex, Alkindi |
| Azurity Pharmaceuticals, INC. | $96.53 | 2023-2024 | Triptodur, Triptodur |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $92.73 | 2019-2020 | |
| Medtronic Minimed, INC. | $84.58 | 2019-2020 | |
| Lilly USA, LLC | $71.79 | 2019-2025 | Mounjaro |
| Companion Medical, INC. | $63.07 | 2019 | |
| Sandoz INC. | $58.68 | 2019 | |
| Kyowa Kirin, INC. | $56.02 | 2024-2025 | Crysvita |
| Sanofi-Aventis U.S. LLC | $43.18 | 2024-2025 | |
| Soleno Therapeutics, INC. | $14.61 | 2025 | Vykat Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcela Vargas Trujillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.